Ponatinib for Pediatric Leukemias and Solid Tumors

We are studying the safety and effectiveness of ponatinib in children with recurrent or hard-to-treat leukemias and solid tumors. This trial aims to help those who have not responded to other therapies.

1-2 years 6-10 visits Safety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Cost Reimbursement Partially Remote Standard Medicines OralHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Iclusig

Iclusig is a cancer medicine used to treat certain types of leukemia, especially when other treatments have not worked.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ponatinib

Ponatinib is a substance that blocks cancer cell growth signals and is used to treat certain types of leukemia, including resistant chronic myeloid leukemia.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Universitair Ziekenhuis Gent

Pediatrische hematologie en oncologie

Ledeberg, Belgium

Assistance Publique Hopitaux De Paris

Pediatric Hematology and Immunology Department

Le Pré-Saint-Gervais, France

Centre Hospitalier Universitaire De Rennes

Pediatric Hemato-Oncology

Rennes, France

Sponsor: Incyte Biosciences International S.a.r.l.

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.